© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 14, 1040-1041,
July 18, 2001
© 2001 Oxford University Press
EDITORIAL |
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Correspondence to: Isaiah J. Fidler, D.V.M., Ph.D., Department of Cancer Biology-173, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (ifidler{at}mdanderson.org).
Cells cannot survive if they lack adequate oxygen and nutrient supply or cannot dispose of toxic molecules. Oxygen can diffuse from capillaries for only 150–200 µm. When distances of cells from a blood supply exceed this, cell death follows (1,2). Thus, the growth and survival of tumor masses beyond 0.5 mm in diameter require neovascularization, i.e., angiogenesis (3).
In this issue of the Journal, Achilles et al. (4) injected human liposarcoma cells (tumor fragments or cells) into the subcutis of severe combined immunodeficient mice. The different tumor fragments and liposarcoma cells gave rise to fast-growing, slow-growing, or small dormant tumors. The growth rate of the tumors correlated directly with microvessel density and correlated inversely with tumor cell apoptosis. The authors concluded that human liposarcomas are heterogeneous for induction of angiogenesis and suggest that the failure to induce angiogenesis can be responsible for the failure to xenotransplant human neoplasms into immunodeficient mice (1). Achilles et al. (4) have provided one more illustration of the "seed and soil" hypothesis.
In 1889, Paget (5) proposed that the growth and spread of cancers occurred when certain favored tumor cells (seed) had a special affinity for the growth milieu provided by specific tissues or organs (soil). A current definition of the seed and soil hypothesis consists of two principles. First, neoplasms are heterogeneous and consist of cells with different biologic properties; second, the outcome of cancer growth and spread depends on multiple interactions of tumor cells with host homeostatic factors (6).
By the time of diagnosis, malignant neoplasms are biologically heterogeneous and contain multiple subpopulations of cells with different properties, including differences in morphology, growth rates, karyotypes, metabolic characteristics, antigenic or immunogenic potential, production of extracellular matrix proteins, cell surface receptors, adhesion molecules, hormone receptors, drug and radiation sensitivities, angiogenic potential, invasiveness, and the ability to metastasize (6).
Angiogenic heterogeneity within a single tumor (zonal or intralesional) between different metastases even in a single organ (interlesional) and different neoplasms of the same histologic type is also documented (7,8). For example, the implantation of murine or human cancer cells into orthotopic sites of nude mice produces progressively growing local tumors. The expression of proangiogenic molecules (and, therefore, vessel density) in the lesions is zonal, i.e., intralesional heterogeneity. Small tumors (3–4 mm in diameter) express more basic fibroblast growth factor (bFGF) and interleukin 8 (IL-8) than large tumors (>10 mm in diameter), whereas more vascular endothelial growth factor (VEGF) is expressed in large tumors. Immunostaining showed a heterogeneous distribution of angiogenic factors within the tumor; expression of bFGF and IL-8 was highest on the periphery of a large tumor, where cell division is maximum. VEGF expression was higher in the center of the tumor (7). Similarly, heterogeneous dependence on angiogenesis was reported recently for cell subpopulations isolated from human melanoma xenografts and cells from teratomas with differential expression of hypoxia-inducing factor-1
(8).
Heterogeneity of blood vessel distribution in surgical specimens of human cancers is well documented (9,10). Benign neoplasms are sparsely vascularized and tend to grow slowly, whereas malignant neoplasms are highly vascularized and fast growing (9). The distribution of vessels in a tumor, however, is not uniform, and Weidner et al. (10) cautioned that, to predict the aggressive nature of human neoplasms, one must determine the mean vessel density (MVD) in the "areas of most intense neovascularization," i.e., tumors exhibit intralesional or zonal heterogeneity for MVD. Similarly, the expression of proangiogenic molecules in surgical specimens of human colon carcinoma was determined by in situ hybridization technique. Matrix metalloproteinase-9 and bFGF were overexpressed at the periphery of the tumor (leading edge), where cells were rapidly dividing, whereas VEGF expression was higher in the center of the lesions (11).
The extent of angiogenic heterogeneity in malignant neoplasms is regulated by the organ microenvironment. For example, human renal carcinoma cells implanted into the kidney of nude mice produce a high incidence of lung metastasis, whereas those implanted subcutaneously are not metastatic (12). Histopathologic examination of the tissues revealed that the tumors growing in the subcutis of nude mice had few blood vessels, whereas the tumors in the kidney had many (12). The subcutaneous (or intramuscular) tumors had a statistically significant lower level of messenger RNA transcripts for bFGF than the tumors in the kidney, whereas the expression of interferon beta (which diminishes transcription of bFGF) was high in epithelial cells and fibroblasts surrounding the subcutaneous tumors and not detected in or around tumors growing in the kidney (13). The production of IL-8 by melanoma cells is regulated by complex interactions with keratinocytes in the skin (14). IL-8 expression can be increased by coculturing melanoma cells with keratinocytes (skin) and inhibited by coculturing melanoma cells with hepatocytes (liver) (15). The organ microenvironment also influences the expression of VEGF/vascular permeability factor. Human gastric cancer cells were implanted into orthotopic (stomach) and ectopic (subcutaneous) organs of nude mice. Tumors in the stomach were highly vascularized, expressed high levels of VEGF, and grew more rapidly than the subcutaneous tumors. In addition, metastasis occurred only from the tumors implanted in the stomach (16).
The successful transplantation of cells from surgical specimens of human neoplasms requires that the cells initially proliferate in the recipient organs and then induce angiogenesis to support additional growth (17). To proliferate, many tumor cells can usurp physiologic growth factors that are produced by the microenvironment when homeostasis is disturbed. For example, after resection of more than half of the liver, the liver undergoes rapid cell division termed "regeneration" without cell division occurring in the kidneys. Similarly, subsequent to nephrectomy, the contralateral kidney compensates by hypertrophy and hyperplasia but the liver does not (17). Autocrine or paracrine growth factors that control the repair of tissues are known to be tissue specific. During liver regeneration, it is common to find high levels of transforming growth factor- (TGF-) and hepatocyte growth factor (HGF) in the circulation (18). The finding that human colon cancer cells capable of growing in the liver parenchyma (Dukes' stage D) express a higher number of functional receptors for TGF- (epidermal growth factor receptor) and HGF (c-met) than do cells with low metastatic potential (Dukes' stage B) supports the hypothesis that the production of liver-specific metastasis results from the proliferation of tumor cells expressing growth factor receptors for tissue-specific paracrine factors involved in homeostasis (19). Indeed, liver regeneration in nude mice stimulates growth of colon cancer cells only, whereas hypertrophy–hyperplasia of the kidney stimulates the growth of renal cancer cells only (17).
In conclusion, the progressive growth of neoplasms and the production of metastasis are dependent on the development of vasculature, i.e., angiogenesis. The extent of angiogenesis is determined by the balance between positive- and negative-regulating molecules, which are released by tumor and host cells in the microenvironment. More than a century ago, Paget enunciated the principle that metastasis occurs only when the right cell (seed) grows in the correct environment (soil). All current data support this concept and recommend that orthotopic implantation of tumor cells in recipient animals is mandatory for studies of tumor progression, angiogenesis, invasion, and metastasis (20,21).
NOTES
Supported in part by Public Health Service grants CA16672, R35CA42107, CA90270, and CA83639 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
REFERENCES
1 Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1995;271:58–65.
2 Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using rabbit cornea. J Natl Cancer Inst 1974;52:413–27.
3
Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award lecture. Cancer Res 1986;46:467–73.
4
Achilles EG, Fernandez A, Allred EN, Kisker O, Udagawa T, Beecken WD, et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001;93:1075–81.
5 Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571–3.
6
Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A Clowes Memorial Award lecture. Cancer Res 1990;50:6130–8.
7 Kumar R, Kuniyasu H, Bucana CD, Wilson MR, Fidler IJ. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res 1998;10:301–11.[Web of Science][Medline]cancerlit;99064567
8 Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001;158:1235–34.
9 Weidner N, Semple JP, Welch JR, Folkman J. Tumor angiogenesis and metastasis -correlation in invasive breast cancer. N Engl J Med 1991;324:1–8.[Abstract]cancerlit;91074199
10
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–87.
11 Kitadai Y, Bucana CD, Ellis LM, Anzai H, Tahara E, Fidler IJ. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am J Pathol 1995;147:1238–47.[Abstract]cancerlit;96065076
12 Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR, Fidler IJ. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994;145:365–74.[Abstract]cancerlit;94330510
13
Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562–6.
14 Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990;9:101–12.[CrossRef][Web of Science][Medline]cancerlit;91070694
15
Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 1995;55:2470–5.
16 Takahashi Y, Mai M, Wilson MR, Ellis LM. Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma. Int J Oncol 1996;8:701–5.
17 Radinsky R. Growth factors and their receptors in metastasis. Semin Cancer Biol 1991;2:169–77.[Medline]cancerlit;92003738
18 Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastases. Cancer Metastasis Rev 1993;12:345–61.[CrossRef][Web of Science][Medline]cancerlit;94108982
19 Fidler IJ, Kerbel RS, Ellis LM. Biology of cancer: angiogenesis. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott; 2001. p. 137–48.
20 Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343–59.[CrossRef][Web of Science][Medline]cancerlit;20221156
21 Fidler IJ. Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst 1995;84:1588–92.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Kuwai, T. Nakamura, S.-J. Kim, T. Sasaki, Y. Kitadai, R. R. Langley, D. Fan, S. R. Hamilton, and I. J. Fidler Intratumoral Heterogeneity for Expression of Tyrosine Kinase Growth Factor Receptors in Human Colon Cancer Surgical Specimens and Orthotopic Tumors Am. J. Pathol., February 1, 2008; 172(2): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Nilsson, G. Armaiz-Pena, R. Takahashi, Y. G. Lin, J. Trevino, Y. Li, N. Jennings, J. Arevalo, S. K. Lutgendorf, G. E. Gallick, et al. Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism J. Biol. Chem., October 12, 2007; 282(41): 29919 - 29926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamura, T. Kuwai, Y. Kitadai, T. Sasaki, D. Fan, K. R. Coombes, S.-J. Kim, and I. J. Fidler Zonal Heterogeneity for Gene Expression in Human Pancreatic Carcinoma Cancer Res., August 15, 2007; 67(16): 7597 - 7604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Dickson, J. B. Hamner, C. J. Streck, C. Y.C. Ng, M. B. McCarville, C. Calabrese, R. J. Gilbertson, C. F. Stewart, C. M. Wilson, M. W. Gaber, et al. Continuous Delivery of IFN-{beta} Promotes Sustained Maturation of Intratumoral Vasculature Mol. Cancer Res., June 1, 2007; 5(6): 531 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Yance Jr and S. M. Sagar Targeting Angiogenesis With Integrative Cancer Therapies Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]
|
|
|
|
|
|
M. B. Nilsson, R. R. Langley, and I. J. Fidler Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine Cancer Res., December 1, 2005; 65(23): 10794 - 10800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Celis, J. M. A. Moreira, T. Cabezon, P. Gromov, E. Friis, F. Rank, and I. Gromova Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients: Toward Dissecting The Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions Mol. Cell. Proteomics, April 1, 2005; 4(4): 492 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ellis Challenges in Translating Antiangiogenic Therapy from Bench to Bedside Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 74 - 77. [Full Text] [PDF]
|
|
|
|
|
|
M. Yang, J. Reynoso, P. Jiang, L. Li, A. R. Moossa, and R. M. Hoffman Transgenic Nude Mouse with Ubiquitous Green Fluorescent Protein Expression as a Host for Human Tumors Cancer Res., December 1, 2004; 64(23): 8651 - 8656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kumar, A. I. Miller, and P. J. Polverini p38 MAPK Mediates {gamma}-Irradiation-induced Endothelial Cell Apoptosis, and Vascular Endothelial Growth Factor Protects Endothelial Cells through the Phosphoinositide 3-Kinase-Akt-Bcl-2 Pathway J. Biol. Chem., October 8, 2004; 279(41): 43352 - 43360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Duda, D. Fukumura, L. L. Munn, M. F. Booth, E. B. Brown, P. Huang, B. Seed, and R. K. Jain Differential Transplantability of Tumor-Associated Stromal Cells Cancer Res., September 1, 2004; 64(17): 5920 - 5924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asosingh, H. De Raeve, E. Menu, I. Van Riet, E. Van Marck, B. Van Camp, and K. Vanderkerken Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity Blood, April 15, 2004; 103(8): 3131 - 3137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Semba, Y. Funahashi, N. Ono, Y. Yamamoto, N. H. Sugi, M. Asada, K. Yoshimatsu, and T. Wakabayashi An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model: Possible Value of Integrin {alpha}2 on Platelets as a Biological Marker Clin. Cancer Res., February 15, 2004; 10(4): 1430 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al. Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects Cancer Res., December 15, 2003; 63(24): 8890 - 8898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yang, L. Li, P. Jiang, A. R. Moossa, S. Penman, and R. M. Hoffman Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells PNAS, November 25, 2003; 100(24): 14259 - 14262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bockhorn, Y. Tsuzuki, L. Xu, A. Frilling, C. E. Broelsch, and D. Fukumura Differential Vascular and Transcriptional Responses to Anti-Vascular Endothelial Growth Factor Antibody in Orthotopic Human Pancreatic Cancer Xenografts Clin. Cancer Res., September 15, 2003; 9(11): 4221 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Solorzano, R. Hwang, C. H. Baker, C. D. Bucana, P. W. Pisters, D. B. Evans, J. J. Killion, and I. J. Fidler Administration of Optimal Biological Dose and Schedule of Interferon {alpha} Combined with Gemcitabine Induces Apoptosis in Tumor-associated Endothelial Cells and Reduces Growth of Human Pancreatic Carcinoma Implanted Orthotopically in Nude Mice Clin. Cancer Res., May 1, 2003; 9(5): 1858 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Uehara, S. J. Kim, T. Karashima, D. L. Shepherd, D. Fan, R. Tsan, J. J. Killion, C. Logothetis, P. Mathew, and I. J. Fidler Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases J Natl Cancer Inst, March 19, 2003; 95(6): 458 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izumi, E. di Tomaso, A. Hooper, P. Huang, J. Huber, D. J. Hicklin, D. Fukumura, R. K. Jain, and H. D. Suit Responses to Antiangiogenesis Treatment of Spontaneous Autochthonous Tumors and Their Isografts Cancer Res., February 15, 2003; 63(4): 747 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ito, Y.-i. Koma, K. Watabe, T. Nagano, Y. Endo, H. Nojima, and Y. Kitamura A Truncated Isoform of the Protein Phosphatase 2A B56{gamma} Regulatory Subunit May Promote Genetic Instability and Cause Tumor Progression Am. J. Pathol., January 1, 2003; 162(1): 81 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Cline, S. Bicciato, C. DiBello, and M. W. Lingen Prediction of in Vivo Synergistic Activity of Antiangiogenic Compounds by Gene Expression Profiling Cancer Res., December 15, 2002; 62(24): 7143 - 7148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ye, C. Feng, S. Wang, X. Liu, Y. Lin, and M. Li Antiangiogenic and Antitumor Effects of Endostatin on Follicular Thyroid Carcinoma Endocrinology, September 1, 2002; 143(9): 3522 - 3528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rak, J. L. Yu, R. S. Kerbel, and B. L. Coomber What Do Oncogenic Mutations Have To Do with Angiogenesis/Vascular Dependence of Tumors? Cancer Res., April 1, 2002; 62(7): 1931 - 1934. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Monsky, C. M. Carreira, Y. Tsuzuki, T. Gohongi, D. Fukumura, and R. K. Jain Role of Host Microenvironment in Angiogenesis and Microvascular Functions in Human Breast Cancer Xenografts: Mammary Fat Pad versus Cranial Tumors Clin. Cancer Res., April 1, 2002; 8(4): 1008 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.K. JAIN Angiogenesis and Lymphangiogenesis in Tumors: Insights from Intravital Microscopy Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 239 - 248. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||